Prevalence of germline TP53 mutation among early onset middle eastern breast cancer patients | Hereditary Cancer in Clinical Practice | Full Text
Implications of driver genes associated with a high tumor mutation burden identified using next‑generation sequencing on immunotherapy in hepatocellular carcinoma
Therapeutic targeting of p53: all mutants are equal, but some mutants are more equal than others | Nature Reviews Clinical Oncology
TP53 mutations as potential prognostic markers for specific cancers: Analysis of data from The Cancer Genome Atlas and the International Agency for Research on Cancer TP53 Database | bioRxiv
IJMS | Free Full-Text | Targeting the Oncogenic p53 Mutants in Colorectal Cancer and Other Solid Tumors | HTML
Mutant p53 drives the loss of heterozygosity by the upregulation of Nek2 in breast cancer cells | Breast Cancer Research | Full Text
The cancer-associated, gain-of-function TP53 variant P152Lp53 activates multiple signaling pathways implicated in tumorigenesis - Journal of Biological Chemistry
Time to first treatment and P53 dysfunction in chronic lymphocytic leukaemia: results of the O-CLL1 study in early stage patients | Scientific Reports
TP53 mutational landscape of metastatic head and neck cancer reveals patterns of mutation selection - eBioMedicine
Cancers | Free Full-Text | TP53 Combined Phenotype Score Is Associated with the Clinical Outcome of TP53-Mutated Myelodysplastic Syndromes | HTML
Targeting Cavity-Creating p53 Cancer Mutations with Small-Molecule Stabilizers: the Y220X Paradigm | ACS Chemical Biology
Targeted point mutations of p53 lead to dominant-negative inhibition of wild-type p53 function | PNAS
Clinical implications of subclonal TP53 mutations in acute myeloid leukemia | Haematologica
Mutant p53 elicits context-dependent pro-tumorigenic phenotypes | Oncogene
TP53 oncomorphic mutations predict resistance to platinum‑ and taxane‑based standard chemotherapy in patients diagnosed with advanced serous ovarian carcinoma
Mutant p53 Drives Cancer Metastasis via RCP-Mediated Hsp90α Secretion - ScienceDirect
Mutant p53 exerts a dominant negative effect by preventing wild-type p53 from binding to the promoter of its target genes | Oncogene
The impact of TP53 mutations and TP53 deletions on survival varies between AML, ALL, MDS and CLL: an analysis of 3307 cases | Leukemia
Targeting the Prion-like Aggregation of Mutant p53 to Combat Cancer | Accounts of Chemical Research
Therapeutic targeting of mutant p53 in pediatric acute lymphoblastic leukemia | Haematologica
Concurrent TP53 Mutations Facilitate Resistance Evolution in EGFR-Mutant Lung Adenocarcinoma - Journal of Thoracic Oncology
Mutations in TP53 and other heterogeneous genes help to distinguish metastases from new primary malignancies | medRxiv
Frontiers | Prevalence of the Brazilian TP53 Founder c.1010G>A (p.Arg337His) in Lung Adenocarcinoma: Is Genotyping Warranted in All Brazilian Patients?
